Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of “Buy” from Analysts

Capricor Therapeutics Inc (NASDAQ:CAPR) has earned an average recommendation of “Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $20.00.

Several brokerages recently commented on CAPR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, September 17th. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a report on Monday. Finally, Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, September 17th.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $5.97 on Tuesday. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $7.28. The company has a market capitalization of $190.91 million, a P/E ratio of -6.86 and a beta of 3.92. The company has a 50-day simple moving average of $4.39 and a 200 day simple moving average of $5.19.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. As a group, equities analysts forecast that Capricor Therapeutics will post -1.24 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares during the period. Renaissance Technologies LLC boosted its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new position in Capricor Therapeutics in the second quarter valued at approximately $426,000. Bank of New York Mellon Corp raised its position in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth $258,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.